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The development of colorectal cancer (CRC) is not only determined by transformed cells
per se, but also by factors existing in their immune microenvironment. Accumulating
scientific evidence has revealed that interleukin (IL)-33, an IL-1 family member, plays
an essential role in the regulation of immune response and is relevant in CRC
pathogenesis. Data from both human and experimental studies demonstrated that IL-33
inhibits host anti-tumor immunity, remodels tumor stroma and enhances angiogenesis,
thereby promoting the development of CRC. These pro-tumor effects of IL-33 are
mainly mediated by IL-33 receptor ST2 (also known as IL-1RL1). Based on those
findings, it is currently hypothesized that the IL-33/ST2 pathway is a potential biomarker
and therapeutic target for colorectal tumorigenesis. Herein, we summarize the recent
discoveries in understanding the critical role of the IL-33/ST2 pathway in contributing to
the pathogenesis of colorectal tumorigenesis and discuss its potential implications for
the future development of effective anti-tumor strategies.
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INTRODUCTION
Colorectal cancer (CRC) is a leading cause of cancers mortality worldwide. The initiation and
development of CRC is not only determined by the genetic and molecular characteristics of
transformed cells per se, but also by factors existing in their immune microenvironment (1–3).
Host immune function is one of the most important factors contributing to the development
of CRC (4–6). The interaction between host immunity and transformed cells might significantly
influence the establishment of CRC (1, 2, 7). It has been known for a number of years that there
is a significant impairment of host anti-tumor immunity during the initiation of CRC because
transformed cells, in order to escape host immune attack, use diverse strategies to suppress
anti-tumor immunity and form a favorable growth milieu. Therefore, there is great interest in
studying the contributing factors of immune microenvironment formation in premalignant and
malignant lesions.
The lack of an effective immune response to tumorigenesis, in spite of the presence of dense
tumor infiltrating lymphocytes in the tumor microenvironment, is believed to be due in some
way to the action of immunosuppressive immune cells/cytokines (8–10). Certain cytokines can
significantly affect the initiation/progression of CRC (1, 11–14), acting not only as the promotors
for tumor cell growth but also as important contributor for the immune suppressive
Abbreviations: CRC, colorectal cancer; IL, interleukin; Treg, regulatory T cell; IR, immunoreactivity; IBD, inflammatory
bowel diseases; COX-2, cyclooxygenase-2; IEC, intestinal epithelial cell; NF-κB, Nuclear Factor-κB; AOM, azoxymethane
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microenvironment formation during tumor development (4,
15–25). Therefore, the improved characterization of cytokine
networks will greatly add help in understanding the cross-talk
between transformed cells and their microenvironment, thereby
presenting the prospect of designing novel translational/targeted
approaches to tumors (14, 26–28). In the study of cytokine
networks in the colorectal tumorigenesis, a greatly altered
cytokine profile during progression of adenomas to CRCs has
been demonstrated (14, 18, 29–31), in which the level of
Th1 cytokines is decreased but the expression level of Th2
cytokines is significantly increased from adenomas to CRCs (5,
6, 32, 33). Further immunohistochemical analysis demonstrated
that adenoma/CRC epithelium significantly contributes to
the production of cytokines (5, 20, 23, 34–38), whereas,
blocking cytokine signaling may suppress the development and
establishment of both premalignant and malignant lesions in
animal models (39, 40). Numerous studies strongly suggest that
cytokines are key factors in influencing the development of CRC
(2, 15, 35, 41, 42).
IL-33 is a novel pro-inflammatory cytokine that belongs to the
IL-1 family. IL-33 plays an important role in the regulation of
host immune responses (43–45) and has been associated with
human inflammatory bowel diseases (IBD) (46, 47), as well as
tumors (48–55). Moreover, studies have also revealed that high
expression of IL-33 is associated with poor prognosis in diverse
cancers and may be a potential prognostic predicator (52, 54–
58). Current data strongly suggest that IL-33 is involved in the
pathogenesis of CRC (19, 59, 60).
In view of the importance of IL-33 in contributing to the
pathogenesis of CRC, herein, we review the critical role of IL-
33 in the pathogenesis of CRC development and evaluate its
potential as biomarker for assessing tumor aggressiveness and
disease prognosis. In addition, the possible role of IL-33 and
its receptor, ST2, as novel biomarkers and therapeutic targets is
discussed.
CELLS EXPRESSING IL-33 AND ITS
FUNCTIONAL RECEPTOR, ST2, IN THE
TUMOR MICROENVIRONMENT
We previously examined cell expressing IL-33 and ST2 in
the human adenoma/CRC microenvironment. Results showed
that IL-33 immunoreactivity (IR) is observed in diverse cells,
including adenoma/CRC cells, CD3 positive lymphocytes, SMA-
alpha positive myofibroblasts and CD34 positive endothelial cells
of tumor-associated microvessels (19). IL-33 functions as a pro-
inflammatory cytokine by binding to the heterodimeric ST2
receptor complex (46). Interestingly, ST2 in the adenoma/CRC
microenvironment is expressed in a very similar cellular pattern
as IL-33. ST2-IR has been clearly identified in adenoma/CRC
cells, lymphocytes, myofibroblasts and endothelial cells of
microvessels (19). Those observations indicate that IL-33 and
ST2 within the adenoma/CRCmicroenvironment originate from
a mixed cellular source and provide important information for
understanding the interaction between IL-33 and its receptor,
ST2, in promoting colorectal tumorigenesis.
PROMOTING EFFECTS OF IL-33 ON THE
DEVELOPMENT OF COLORECTAL
TUMORIGENESIS
Chronic inflammation is a major risk factor for the development
of CRC (1, 15, 61), and IL-33 is a potent pro-inflammatory
cytokine that plays a critical role in the initiation of colorectal
mucosal inflammation (62, 63). Thus, studies regarding the role
of IL-33 in the CRC development in animal models has attracted
much attention and evidence is accumulating.
The one animal study of interest with respect to IL-33 and
the formation of premalignant adenoma was performed in mice.
Maywald et al. examined the promoting effect of IL-33 in
the formation of polyps (adenomas) in traditional ApcMin/+
mice with an IL-33 deficient background (59). They found
that IL-33 deficiency significantly reduced the formation of
intestinal polyposis (adenoma) and mast cell accumulation in
adenomatous polyps, suppressing the expression of mast cell-
derived proteases and cytokines known to promote polyposis
in ApcMin/+ mice (59). Thus, their findings suggest that IL-
33 promotes the formation of intestinal adenomas through
coordinated activation of stromal cells and formation of a pro-
tumorigenic microenvironment (59).
We have examined the expression profile of IL-33 in
human adenomas and found that expression levels of IL-
33 mRNA are markedly increased in adenoma tissues
(19). This finding might imply that IL-33 is an early
immune response element reacting to the initiation of
premalignant adenomas. Immunohistochemical results
revealed that IL-33-IR was highly expressed in adenoma
cells, lymphocytes, stromal cells (myofibroblasts) and
microvessels, indicating an autocrine/paracrine loop in
those cells. Particularly, the density of IL-33-positive
microvessels was significantly increased in adenoma stroma
compared to normal controls (19). These findings suggest
that elevated IL-33 may participate in the regulation of
tumor associated angiogenesis during the progression of
adenomas. Indeed, we have found that the expression
level of IL-33 mRNA is associated with dysplastic degree
in adenomas (19). Those findings suggest the hypothesis
that IL-33 participates in the pathogenesis of premalignant
adenomas.
Regarding the role of IL-33 in the pathogenesis of CRC,
numerous studies have been conducted in animals and humans.
Using mice treated with the chemical carcinogen
azoxymethane (AOM) and the inflammatory inducer dextran
sodium sulfate (DSS), Islam et al. revealed that epidermal
growth factor is a key growth factor in intestinal epithelial cell
(IEC)-derived IL-33 promotion of tumorigenesis (64). Most
current human studies are performed in established human
CRCs (19, 59, 63). Results have showed increased expression
levels of IL-33 at both the protein and transcriptional levels in
human CRC tissues (19). Interestingly, increased expression
levels of IL-33 and ST2 were more frequently observed in
low-grade adenocarcinomas than high-grade adenocarcinomas
(63). Our immunohistochemical analysis has shown that many
types of cells within the CRC microenvironment can express
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both IL-33 and ST2. As illustrated in adenomas, we also found
that both IL-33- and ST2-IRs are expressed in CRC cells, CD3
positive lymphocytes, SMA-alpha positive myofibroblasts, and
CD34 positive microvessels within the CRC microenvironment.
Our findings suggest that elevated expression of IL-33 and ST2 in
CRC tissues may come from a mixed cellular source, and IL-33
could have far-reaching biological effects on diverse cells within
the CRC microenvironment.
CONTRIBUTION OF DIFFERENT FORMS
OF THE IL-33 RECEPTOR TO THE
DEVELOPMENT OF COLORECTAL
TUMORIGENESIS
The IL-33 receptor exists in the following two forms as splice
variants: (1) a soluble form (sST2), which acts as a decoy
receptor, sequesters free IL-33, and does not signal; and (2)
a membrane-bound form (ST2), which activates MyD88/NF-
κB signaling to enhance mast cell, Th2, Treg cells, and innate
lymphoid cell type 2 functions (65). Therefore, the functions
for these two receptor forms are completely different. It has
been reported that the expression level of ST2 is significantly
increased in both animal and human CRC tissues (19, 63).
Moreover, the administration of ST2 antibody in ApcMin/+
mice results in significantly reduced both tumor number and
size compared to control mice, accompanied by a significant
inhibition of proliferation and angiogenesis, with increased
apoptosis in adenomatous polyps (59). Mertz KD and colleagues
examined the role of ST2 in the development of colorectal
tumorigenesis in an ST2–/– deficient mouse model (63). They
found that deficiency of ST2 in mice results in a protective effect
against AOM/DSS-triggered CRC, with significantly reduced
tumor load compared with control mice. In addition, their results
also suggested that the promoting effect of the IL-33/ST2 axis
on colonic tumorigenesis occurs via the production of IL-6 (63).
Their results strongly suggest that ST2 is a key mediator for
IL-33 induced colorectal tumorigenesis (63). We examined the
expression profile of ST2 in both human adenomas and CRCs
(19). Results demonstrated that increased expression of ST2 is
found in adenoma tissues and persists to in CRC tissues. ST2-
IR is highly expressed in adenoma/CRC cells, stromal cells and
microvessels within the tumormicroenvironment (19). Since ST2
plays an essential role in the regulation of host immune response,
Treg accumulation, and angiogenesis, our findings indicates that
increased expression of ST2 participates in the development of
CRC.
The function of sST2 is different from that of ST2, and
the role of sST2 during the progression of CRC has also been
examined. One study revealed that the expression level of sST2
in cancer tissues is lower than that in adjacent nontumor tissues.
In addition, patients with advanced TNM stage have lower
expression of sST2 (66). They only found differences in ST2,
sST2 was only measured in plasma with no difference between
patients vs. healthy subjects. Which suggests that the ST2 variant
might have an anti-tumorigenic role in the CRC. In contrast to
O’Donnell’s results (66), Miho Akimoto et al. reported that sST2
is a negative regulator for tumor growth and metastasis (67).
They found that expression levels of sST2 are inversely associated
with themalignant growth of CRC, and sST2 is down regulated in
highly metastatic cells compared with low metastatic human and
mouse CRC cells. Knockdown of sST2 in low metastatic SW480
cells (CRC cell line derived from the primary tumor site) with
sST2 short hairpin RNA (shRNA) enhances tumor cell growth
and tumor formation, whereas its overexpression in highly
metastatic SW620 cells (CRC cell line derived from themetastatic
site from the same patient) inhibits these processes. The SW480-
shsST2 cells efficiently formed tumors (7 out of 7 mice), whereas
the SW480-shCont (the control shRNA-expressing) cells seldom
formed tumors (1 out of 7 mice). It has been previously shown
that IL-33 exhibited a proangiogenic effect in human umbilical
vein endothelial cells (HUVECs) via Akt signaling (68). The
authors have therefore examined the ratio of phospho-Akt/total
Akt in HUVECs treated with rIL-33 alone or in combination with
rsST2. They found that rIL-33 promoted Akt phosphorylation,
and phosphorylation was decreased by co-treatment with rsST2.
Similarly, a thymidine incorporation assay, migration assay and
tube formation assay using a two-dimensional Matrigel revealed
the inhibitory effect of rsST2 on rIL-33-induced responses of
HUVECs (67). Thus, they concluded that sST2 is involved in
the regulation of IL-33 on angiogenesis. These two reports have
provided different results. Therefore, further studies regarding
the exact role of sST2 in CRC progression still needed.
Collectively, these results obtained from both animal and
human studies suggest that colorectal tumorigenesis elicits a
strong IL-33 response, and this response may contribute to the
development of both premalignant and malignant lesions.
MECHANISMS OF IL-33 PROMOTING THE
DEVELOPMENT OF CRC
The precise mechanisms whereby IL-33 promotes the
development of CRC remain unclear, though several potential
mechanisms have been hypothesized and evaluated.
A direct effect on colorectal epithelial cells: A direct promoting
effect of IL-33 on cell transformation has been observed in other
types of human cancers (49). However, Mertz KD et al. revealed
that the promoting effect of IL-33 on the development of CRC
in mice does not directly affect the proliferation of tumor cells in
animal CRC models (63).
Induction of other pro-tumorigenic factors: Cyclooxygenase-
2 (COX-2), IL-6 and IL-17A are potent pro-tumorigenic factors
that encourage the development of CRCs (22, 24, 30, 69,
70). It was recently shown that the stimulating effect of IL-
33 on cell proliferation in vitro with primary CRC cells, as
well as CRC cell lines, depends on activation of the COX-
2/PGE2 pathway (71). The COX-2 selective inhibitor and PGE2
neutralizing antibody significantly attenuated such proliferation-
promoting effects induced by IL-33 administration (71). IL-
17A is another pro-inflammatory cytokine with a strong pro-
tumorigenic capacity. Studies have also shown that serum
concentrations of IL-33 are associated with upregulated levels of
IL-17A in patients with autoimmune hepatitis, whereas specific
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inhibition of IL-33 by treatment with a specific neutralizing
antibody significantly reversed the level of IL-17A in a murine
model with autoimmune hepatitis (72). Moreover, a recent study
demonstrated that IEC-derived IL-33 regulates the accumulation
of Th17 cells (a main cellular source of IL-17A) in the small
intestine (73). In addition, IL-6 is also reported to be an
important mediator for IL-33 in promoting the formation of
CRC in ST2 deficient mice (63). Since IL-6 is an upstream
stimulator of IL-17A production from Th17 cells, the IL-33-IL-
6-IL-17A pathway may play a critical role in the development of
CRC.
Remodeling tumor stroma and pro-angiogenesis: IL-33
markedly stimulates myofibroblasts to produce several types of
extracellular matrix components including MMP2, MMP9, and
growth factors associated with CRC tumor growth, progression
and metastasis (63, 67, 74). Such stromal remodeling effects of
IL-33 have been shown to promote tumor cell growth and liver
metastasis in IL-33-deficient mice with a metastatic murine CRC
cell line (60).
IL-33 is a cytokine with strong pro-angiogenic capabilities
(68, 75, 76), and one of the potential mechanisms for IL-33
in promoting CRC progression maybe due to the enhanced
angiogenesis (60). We know that the IL-33 receptor, ST2, is
highly expressed in the endothelial cells of microvessels that
mediate potential proangiogenic effects of IL-33 (19, 68). Yeon-
Sook Choi et al. demonstrated that IL-33 increases proliferation
and differentiation of human endothelial cells and increases
angiogenesis in vivo (68). We previously demonstrated increased
densities of IL-33 positive and ST2 positive microvessels in
adenoma/CRC stroma, suggesting that microvessels are not
only the cellular sources of IL-33 and ST2 may also be
autocrine or paracrine targets for IL-33/ST2 in regulating
angiogenesis in the adenoma/CRC microenvironment (19). IL-
33 can stimulate the production of pro-angiogenic factors
(77, 78), vascular endothelial growth factor (VEGF), and IL-
8, are well-known pro-angiogenic factors in human cancers
including CRC (18, 79). There is evidence to show that IL-
33 strongly stimulates production of VEGF and IL-8 in vitro
(77, 78). We and others have reported significant increase
of IL-8 and VEGF expression in human adenoma and CRC
specimens (18, 19, 80), which are similar to the expression
profile of IL-33 in adenoma and CRC specimens. Therefore,
these findings may suggest a possible regulatory effect of IL-
33 on the induction of pro-angiogenic factors during colorectal
tumorigenesis.
Induced suppressive immune cell accumulation: Numerous
studies have demonstrated that IL-33 can greatly influence
various immune cells during differentiation, immune responses
and homeostasis (45, 65). Thus, one of the possible mechanisms
for IL-33 in promoting human cancer progression is through
increased accumulation of immunosuppressive cells within the
tumor microenvironment and by diminishing innate anti-
tumor immunity. The IL-33/ST2 axis has a potential role in
the expansion and function of diverse immune cells (65).
Accumulation of Tregs in the tumor microenvironment is
a common phenomenon in both colorectal premalignant
and malignant lesions (8, 81, 82). IL-33 can induce the
enhanced recruitment of suppressive immune cells such
as CD11b+ GR1+ and CD11b+ F4/80+ myeloid cells
and Tregs into the tumor site, where these cells have
a strong impact on immune microenvironment remodeling
(60, 83). Exogenously administered recombinant mouse IL-
33 significantly potentiates tumor burden and induces ST2
positive Tregs infiltrated into tumor masses. In contrast,
neutralizing IL-33 or ST2 by administration of antibodies
remarkably inhibits tumor size and decreases the density of
ST2 positive Tregs inside tumor masses in tumor-bearing
mice (84). Thus, the accumulation of suppressive immune
cells in the tumor microenvironment might play a role
in the regulation of host immune response during CRC
development.
Therefore, although the exact mechanism of IL-33’s
promotion of CRC development is still unknown, its pro-
tumor function in the colorectal mucosa is likely due to a
combination of several mechanisms (see Figure 1).
COULD IL-33 BE A POTENTIAL
BIOMARKER AND NEW THERAPEUTIC
TARGET FOR COLORECTAL
TUMORIGENESIS?
It was previously demonstrated that IL-33 and ST2 at mRNA
and protein levels are increased in both premalignant and
malignant tissues (19, 63, 85). In our study, we investigated the
clinical significance of IL-33 and ST2 as novel clinicopathological
biomarkers in patients with premalignant adenomas and CRCs.
General analysis revealed that no clinicopathological parameters
were associated with tissue levels of either IL-33 or ST2 mRNAs
in patients with adenomas. However, tissue expression levels
of ST2 in CRC patients were associated with TNM stage, and
patients with advanced TNM stage had a higher ST2 mRNA
level than those with early stage disease (19). It has been
established that the expression level of IL-33 is associated with
poor prognosis and predicts unresponsiveness to chemotherapy
in certain cancers, including CRC (55, 56, 58, 86). We therefore
analyzed the relationship between expression levels of IL-33/ST2
and overall survival in patients with CRCs. However, our
Kaplan-Meier analysis did not confirm a correlation between
concentrations of either IL-33 or ST2 at the mRNA level with
overall survival times in CRC patients (19). These results indicate
that whether high expression levels of IL-33 and ST2 mRNA
could serve as a marker of disease aggressiveness in patients
with CRC is still questionable. IL-33 and ST2 are expressed
in a variety of cells, including epithelial cells, stromal cells,
infiltrating lymphocytes and microvessels (19), and IL-33 and
ST2 at the mRNA level of whole CRC specimens quantified
by real-time PCR may not differentiate the expression level
of IL-33 and ST2 in various compartments of the tumor
microenvironment. Therefore, a future priority is to investigate
the relationship between expression levels of IL-33 and ST2 in
various compartments and clinicopathological variables.
Many efforts have been directed toward the inhibition
of cytokine networks as new therapeutic targets for CRC
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FIGURE 1 | A schematic representation of the potential mechanisms of IL-33 in contributing to the development of colorectal premalignant and malignant lesions.
development (87). The IL-33/ST2 axis as a new therapeutic
target during the CRC development has also been evaluated. One
study to show that the blockade of ST2 signaling through the
administration of a ST2 antibody suppresses the development of
CRC in ApcMin/+ mice (59). Similarly, ST2 deficiency reduces
tumor number, size, and dysplastic grade in the intestine of
AOM/DSS-dosed mice (63, 88).
Because angiogenesis is a critical step for the growth,
expansion and metastasis of CRCs, targeting angiogenesis
has become one of the therapeutics for treating CRCs (87).
As we stated previously, IL-33 is a potent pro-angiogenic
factor that markedly enhances angiogenesis during tumor
development. We and others have previously demonstrated
that both IL-33 and ST2 are highly expressed in tumor-
associated microvessels, implying autocrine stimulation of
angiogenesis during the progression of CRC (19). Cytokine
signaling can be easily targeted pharmacologically (89), and
several studies have examined the inhibitory efficacy of IL-
33 or ST2 signals in murine CRC models. However, cytokine
networks in tumors are very complex; one cytokine may have
a wide range of biological effects, while different cytokines
may possess the same function (38). Although most studies
demonstrate that IL-33 promotes the development of CRC,
the antitumor effect of IL-33 has also been reported at least
in some tumor models (90–92). Therefore, one should take
into consideration that IL-33 might have a more complex
effect on the development of CRC when designing therapeutic
interventions targeting IL-33 or ST2 signaling. Fundamental
questions regarding the mechanisms of IL-33 or ST2 signal




Cumulative evidence from both animal and human studies
strongly supports that IL-33 plays an important role in
dictating the development and growth of colorectal cancer
through regulation of host anti-tumor immunity, angiogenesis
and stromal remodeling that are found in the tumor
microenvironment. Based on the findings of the studies outlined
in this review, IL-33 as a potential contributor and therapeutic
target for the development of colorectal tumorigenesis has been
considered, which may benefit the design of new medicines for
the treatment of CRC. However, many fundamental questions
remain.
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